parsaclisinib

Phase 3Small molecule

parsaclisinib is one of 10 small molecule programs targeting Warm Autoimmune Hemolytic Anemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Warm Autoimmune Hemolytic AnemiaActive, not recruiting

Warm Autoimmune Hemolytic AnemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Warm Autoimmune Hemolytic Anemia

#DrugCompanyPhaseTrials

Wayrilz

GGenzyme, a Sanofi Company

Phase 3

2 2

Ianalumab

Novartis

Phase 3

1 3

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

1 4

Obexelimab

ZZenas BioPharma (USA), LLC

Phase 3

1 5

ALXN1830

AstraZeneca

Phase 2

3 6

M281

MMomenta Pharmaceuticals, Inc.

Phase 3

1 7

parsaclisinib

Incyte

Phase 3

1 8

Fabhalta

Johnson & Johnson

Preclinical

1 9

ANX005

AAnnexon, Inc.

Phase 2

—10

RVT-1401

IImmunovant Sciences GmbH

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Warm Autoimmune Hemolytic Anemia1 trial

Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia

Terminated· Incyte logo

Incyte·Phase 3·NCT05073458·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for parsaclisinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — parsaclisinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for parsaclisinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Incyte company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Incyte

parsaclisinib

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Warm Autoimmune Hemolytic Anemia1 trial

References

Drug Info

Quick Facts

Related News